Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium sulfide (CaS) is an inorganic compound that serves as a stimuli-responsive, slow-release donor of hydrogen sulfide (H2S) and calcium ions (Ca2+). In biomedical research, CaS is frequently formulated as nanoparticles or nanoclusters designed to degrade in the acidic microenvironment of tumors or ischemic tissues. This hydrolysis process releases H2S, a gasotransmitter with dose-dependent effects, and Ca2+, which can induce intracellular calcium overload. The resulting oxidative stress, mitochondrial dysfunction, and inhibition of ATP synthesis lead to selective cell death (apoptosis or pyroptosis) in various cancers, including melanoma, lung adenocarcinoma, and cervical cancer. Additionally, CaS nanoparticles have demonstrated neuroprotective potential in ischemic stroke models by providing sustained H2S delivery and have been explored for bone regeneration in osteoporosis. Beyond its therapeutic roles, CaS is a well-known phosphor used in optoelectronics, anticounterfeiting, and environmental applications such as heavy metal remediation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium sulfide.